Featured Research

from universities, journals, and other organizations

Erlotinib dosing in lung cancer depends on smoking status

Date:
January 12, 2010
Source:
American Association for Cancer Research
Summary:
Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.

Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.

"Increased doses may lead to better outcomes, so we are trying to determine how high we can go with this agent without having to stop," said Lynsay Waller, M.D., a fellow at Wake Forest University, who presented her data at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held here Jan. 11-14, 2010.

Waller and colleagues evaluated 25 patients and put them on a chemotherapy regimen that began with docetaxel, cisplatin and pegfilgrastim growth factor support. The researchers then started administering erlotinib at 150 mg daily for non-smokers and 300 mg daily for smokers. These doses were increased every two weeks until development of grade 2 toxicity, when the doses stabilized. If grade 3 toxicity emerged, the doses were cut back by 75 mg a day.

Doses reached as high as 525 mg for smokers and 225 mg for non-smokers, but by the end of the study most smokers had a maximum tolerated dose of 300 mg compared with 225 mg for non-smokers.

The most common reasons for discontinuation of therapy was grade 2 rash, grade 2 or grade 3 diarrhea or grade 3 dehydration.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Erlotinib dosing in lung cancer depends on smoking status." ScienceDaily. ScienceDaily, 12 January 2010. <www.sciencedaily.com/releases/2010/01/100112165119.htm>.
American Association for Cancer Research. (2010, January 12). Erlotinib dosing in lung cancer depends on smoking status. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2010/01/100112165119.htm
American Association for Cancer Research. "Erlotinib dosing in lung cancer depends on smoking status." ScienceDaily. www.sciencedaily.com/releases/2010/01/100112165119.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins